Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome
暂无分享,去创建一个
C. Obinger | M. Prévost | B. Elfving | R. Conotte | J. Colet | Jalal Soubhye | M. Gelbcke | C. Delporte | P. Van Antwerpen | J. Néve | Iyas Aldib | M. Vanhaeverbeek | A. Rousseau | P. Furtmüller | F. Dufrasne | K. Zouaoui-Boudjeltia | Manuel Podrecca | J. Nève | Raphael Conotte
[1] B. Cravatt,et al. Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling. , 2013, Biochemistry.
[2] E. Gouaux,et al. Structural basis for action by diverse antidepressants on biogenic amine transporters , 2013, Nature.
[3] Eric Gouaux,et al. X-ray structure of dopamine transporter elucidates antidepressant mechanism , 2013, Nature.
[4] C. Obinger,et al. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. , 2013, Journal of medicinal chemistry.
[5] L. Vanhamme,et al. Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. , 2012, Talanta.
[6] M. J. Núñez,et al. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. , 2011, Basic & clinical pharmacology & toxicology.
[7] A. Kettle,et al. 2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation* , 2011, The Journal of Biological Chemistry.
[8] M. Saridi,et al. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis , 2011, Medical science monitor : international medical journal of experimental and clinical research.
[9] P. Libby,et al. Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.
[10] H. Mayberg,et al. Stuck in a rut: rethinking depression and its treatment , 2011, Trends in Neurosciences.
[11] H. Lane,et al. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. , 2010, Thrombosis research.
[12] Rodolfo do Couto Maia and Carlos Alberto Manssour Fraga. Discovery of Dual Chemotherapy Drug Candidates Designed by Molecular Hybridization , 2010 .
[13] C. Obinger,et al. Structure-based design, synthesis, and pharmacological evaluation of 3-(aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. , 2010, Journal of medicinal chemistry.
[14] B. Beno,et al. Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors. , 2010, Journal of medicinal chemistry.
[15] M. Maes,et al. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. , 2010, Journal of affective disorders.
[16] W. Siess,et al. Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood , 2010, Thrombosis and Haemostasis.
[17] B. Jin,et al. Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson’s Disease , 2010, The Journal of Immunology.
[18] S. Nicholls,et al. Biomarkers of inflammation and oxidative stress in atherosclerosis. , 2010, Biomarkers in medicine.
[19] Sang Ki Park,et al. Depression research: where are we now? , 2010, Molecular Brain.
[20] Masafumi Ueno,et al. Basic principles of platelet biology and clinical implications. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[21] K. Boudjeltia,et al. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. , 2009, Talanta.
[22] I. López-Vílchez,et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity , 2009, Thrombosis and Haemostasis.
[23] Anil Kumar,et al. Protective effects of antidepressants against chronic fatigue syndrome – induced behavioral changes and biochemical alterations , 2009, Fundamental & clinical pharmacology.
[24] J. Richards. Patent issues relating to hybrid drugs , 2008 .
[25] V. Vaccarino,et al. Association of Major Depressive Disorder with Serum Myeloperoxidase and Other Markers of Inflammation: A Twin Study , 2008, Biological Psychiatry.
[26] B. Meunier,et al. Hybrid molecules with a dual mode of action: dream or reality? , 2008, Accounts of chemical research.
[27] L. Çelik,et al. Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. , 2008, Journal of the American Chemical Society.
[28] C. Obinger,et al. Myeloperoxidase: a target for new drug development? , 2007, British journal of pharmacology.
[29] Jimin Pei,et al. PROMALS: towards accurate multiple sequence alignments of distantly related proteins , 2007, Bioinform..
[30] M. Nazıroğlu,et al. Protective Effects of Lamotrigine, Aripiprazole and Escitalopram on Depression-induced Oxidative Stress in Rat Brain , 2007, Neurochemical Research.
[31] D. Atar,et al. Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study , 2007, Neuropsychopharmacology.
[32] Ben M. Webb,et al. Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.
[33] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[34] B. Beno,et al. Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. , 2005, Journal of medicinal chemistry.
[35] S. Hazen,et al. Myeloperoxidase and cardiovascular disease. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[36] S. Klebanoff. Myeloperoxidase: friend and foe , 2005, Journal of leukocyte biology.
[37] C. Obinger,et al. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design. , 2005, Biochemical pharmacology.
[38] J. Macor,et al. Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs). , 2005, Bioorganic & medicinal chemistry letters.
[39] B. Elfving,et al. The Chicken Serotonin Transporter Discriminates between Serotonin-selective Reuptake Inhibitors , 2004, Journal of Biological Chemistry.
[40] O. Wiborg,et al. Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants , 2004, The European journal of neuroscience.
[41] S. Khanzode,et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors , 2003, Redox report : communications in free radical research.
[42] D. Atar,et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin , 2003, European journal of heart failure.
[43] R. de la Torre,et al. Synthesis of the major metabolites of paroxetine. , 2003, Bioorganic chemistry.
[44] W. Pearson,et al. Current Protocols in Bioinformatics , 2002 .
[45] R. Blakely,et al. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. , 2001, Molecular pharmacology.
[46] E. Bosmans,et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.
[47] Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.
[48] H. Neels,et al. Immune Disturbances in Treatment‐Resistant Depression: Modulation by Antidepressive Treatments , 1997 .
[49] E. Bosmans,et al. Indicators of immune activation in major depression , 1996, Psychiatry Research.
[50] B. Vogt,et al. Neurotoxic effects of partially oxidized serotonin: tryptamine-4,5-dione , 1989, Brain Research.
[51] S. Håkansson,et al. Comparative acute toxicity of paroxetine and other antidepressants , 1989, Acta psychiatrica Scandinavica. Supplementum.
[52] J. Metcalf,et al. Myeloperoxidase deficiency: prevalence and clinical significance. , 1981, Annals of internal medicine.
[53] A. Kettle,et al. Serotonin as a physiological substrate for myeloperoxidase and its superoxide-dependent oxidation to cytotoxic tryptamine-4,5-dione. , 2009, The Biochemical journal.
[54] K. Ley,et al. Role of platelets in the development of atherosclerosis. , 2004, Trends in cardiovascular medicine.
[55] W. Daniel,et al. Platelets and Blood Cells , 2004 .
[56] W. J. Steen. Assessing overmedication: Biology, philosophy and common sense , 2003 .
[57] W. J. van der Steen. Assessing Overmedication: Biology, Philosophy and Common Sense , 2003, Acta biotheoretica.
[58] J. Kelly,et al. The toxicity profile of a single dose of paroxetine: an alternative approach to acute toxicity testing in the rat. , 2001, Pharmacology & toxicology.